Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Neurology | Family Medicine
Search Medical Condition
Alzheimer's Disease Clinical Trials
A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (654) clinical trials
Early Alzheimer’s disease
A global research study needs people aged 50 to 85 concerned by their memory changes. If you or someone you know is experiencing memory loss or has early Alzheimer’s disease, you may qualify and receive at no cost: Investigational drug Study-related care from a local study doctor Reimbursement for travel ...
Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression
A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease.
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD).
This is a Phase II, randomised, multi-centre, double-blind, placebo-controlled proof-of-concept study to assess the safety, tolerability and efficacy of oral Xanamem™ once daily in adult subjects with mild dementia due to AD.
Randomized, Double-Blind, Placebo-Controlled, 2-Arm, 6-Month, Brain Imaging and Safety Study of TRx0237 in Subjects With Mild Alzheimer's Disease
The purpose of this study is to determine the safety and efficacy of TRx0237 8 mg/day in the treatment of subjects with mild Alzheimer's Disease compared to placebo.
A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.
The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease
The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety ...
A Pilot, Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Tolerability, Efficacy, and Pharmacokinetics of AD-35 in Subjects With Mild to Moderate Alzheimer's Disease.
Multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate the safety and tolerability, efficacy, and PK of 60 mg and 90 mg AD-35 administered QD during 6 months of double-blind treatment followed by a second 6 months of open-label treatment to subjects with mild to moderate AD.
A study to evaluate the safety, tolerability, and efficacy of LY3002813 in individuals with early Alzheimer's disease
The Trailblazer study is investigating the safety, tolerability, and efficacy of an investigational drug on symptoms of cognitive and functional decline in individuals with early Alzheimer's disease. The study drug is an infusion that will be administered once per week for 75 weeks. The study will last approximately two and ...
A study to evaluate brain imaging and the safety of Leuco-methylthioninium bis(hydromethanesulfonate) (LMTM) in subjects with mild Alzheimer's disease.
The TauRX study is investigating the efficacy and safety of an investigational drug on symptoms of cognitive decline in individuals with mild Alzheimer's disease, compared to a placebo. The study drug is a tablet which is taken by mouth twice per day. The study will last approximately 8 months.
